AVROBIO, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Erik John Ostrowski
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 300 Cambridge MA United States of America 02139
- IPO Date
- Jun 21, 2018
- CIK
- 0001681087
- Website
- avrobio.com
- Similar Companies
- Business
- AVROBIO, Inc., a company originally focused on ex vivo lentiviral gene therapies, completed a definitive merger with Tectonic Therapeutic, Inc. on June 21, 2024. The combined entity now operates as Tectonic Therapeutic, Inc., with its shares trading on the Nasdaq Global Market under the ticker symbol "TECX". Prior to this transaction, AVROBIO ceased further development of its gene therapy programs, including those for Fabry disease and Gaucher disease. The newly formed Tectonic Therapeutic is dedicated to advancing a pipeline of G-protein coupled receptor (GPCR)-targeted therapeutic proteins, leveraging its proprietary GEODe platform. This platform is designed to discover novel biologic drugs for GPCRs that have historically been challenging targets. The company's lead investigational candidate, TX45, is an Fc-relaxin fusion protein currently being advanced for Group 2 Pulmonary Hypertension in patients with Left Heart Disease and Preserved Ejection Fraction. Initial Phase 1a clinical data for TX45 were expected in mid-2024, with Phase 1b results anticipated in 2025 and Phase 2 randomized data projected for 2026. Furthermore, Tectonic is progressing a second program targeting Hereditary Hemorrhagic Telangiectasia (HHT), with human studies planned to commence in late 2025 or early 2026. AVROBIO was originally incorporated in 2015 and headquartered in Cambridge, Massachusetts. Following the merger, the corporate headquarters for Tectonic Therapeutic, Inc. is now located in Watertown, Massachusetts.
Why Is Avrobio (AVRO) Stock Moving Today?
Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic
AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders
AVROBIO and Tectonic Therapeutic Announce Merger
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVROBIO to Explore Strategic Alternatives
How to Handle Penny Stocks Volatility in 2023
Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Trading Penny Stocks? Top Stock Market News for February 9th, 2022
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks